Patent intelligence · US
US 12005061
Ophthalmic formulations of methotrexate
Ophthalmic formulations of methotrexate
Patent details — US 12005061
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 11, 2024
- Expiration
- Jun 6, 2044
- Applicant
- Aldeyra Therapeutics, Inc.
- Claims
- 27
- CPC classes
- A61K, A61K31/519, A61K47/02, A61K47/10
Quick answer
US 12005061 (Ophthalmic formulations of methotrexate) is held by Aldeyra Therapeutics, Inc.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aldeyra Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/519, A61K47/02, A61K47/10, A61K47/26, A61K9/0048
More from Aldeyra Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12240816
Deuterated compounds and uses thereof
granted -
US 12128013
Toxic aldehyde related diseases and treatment
granted -
US 12097188
Compositions and methods for the treatment of macular degeneration
granted -
US 12064516
Pharmaceutical formulations and uses thereof
granted -
US 12029735
Polymorphic compounds and uses thereof
granted -
US 12006298
Polymorphic compounds and uses thereof
granted -
US 12005060
Ophthalmic formulations of methotrexate
granted
Frequently asked questions
What is US patent 12005061?
US 12005061 (Ophthalmic formulations of methotrexate) is held by Aldeyra Therapeutics, Inc.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12005061?
Aldeyra Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 12005061 expire?
Our index shows an expiration date of Jun 6, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.